Search filters

Filters
Clear All

Phase

  • 1
  • 1
  • 12
  • 14
  • 5
  • 1
  • 13

Found 14 Kidney Disease trials

A listing of Kidney Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 LCAT Deficiency Disorders: natural history and identification of biomarkers
1-99 years
All genders
Familial lecithin:cholesterol acyl transferase (LCAT) deficiency (FLD) is a rare, hereditary disease with no treatment. It is caused by mutations in the gene for LCAT, an enzyme that is made in the liver and plays a role in the body’s ability to process (“metabolize”) cholesterol. People with FLD have very …
 Continuation of the nuMoM2b Heart Health Study
18-99 years
Female
Interventional
The nuMoM2b Heart Health Study (nuMoM2b-HHS) has followed a demographically diverse cohort of women enrolled and richly phenotyped during their first pregnancy, with data and biospecimens prospectively collected for up to 7 years thereafter. The overarching scientific goal of this study is to define the relationship between adverse pregnancy outcomes …
 Study to Evaluate the Efficacy and Safety of Nefecon Treatment in Patients With IgA Nephropathy Who Have Completed Study Nef-301
18-99 years
All genders
Interventional
This is a Phase 3b, multicenter, open-label extension (OLE) study to evaluate the efficacy and safety of Nefecon treatment in patients with IgAN who have completed the Phase 3 Study Nef 301 and continue to be treated with a stable dose of RAS inhibitor therapy (ACEIs and/or ARBs). Patients who …
18-100 years
All genders
The research study is being conducted to test how providing trauma-informed care training to health care providers and support from a community health worker to patients may affect health outcomes for people with lower kidney functioning, also known as “chronic kidney disease.” Chronic kidney disease can be caused by health …
99 years and younger
All genders
Study is enrolling participants with IgA nephropathy to study safety and effectiveness of sparsentan in combination with SGLT2 inhibition. Participants are enrolled for 28 weeks and if taking any ACEI or ARB therapies, must discontinue prior to Day 1 visit.
 Noninvasive Quantification of Renal Oxygen Utilization in Early Kidney Disease
18-59 years
Accepts healthy volunteer
All genders
Type 2 diabetes is the most common cause of chronic kidney disease (CKD). In people with diabetes, the kidneys do not function normally and continuously require more oxygen to remove waste from the body. This process, in-turn, depletes the available supply of oxygen, causes damage to the tissue itself, and …
 CureGN-Diabetes: Ancillary Study to CureGN
18-99 years
All genders
Interventional
There are several different types of glomerular diseases, such as minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), membranous nephropathy (MN), and immunoglobulin A nephropathy (IgAN). Over time, these diseases may cause kidney damage. Because these kidney diseases are rare, it is difficult for individual researchers to gather a large …
 HOPE Trial
18-99 years
All genders
HOPE is a randomized clinical trial that will evaluate approaches to reducing pain and opioid use among patients with chronic pain who are receiving maintenance hemodialysis for end-stage renal disease. The hypothesis is that pain coping skills training will be effective at reducing pain and opioid use, and that buprenorphine …
99 years and younger
All genders
Study is enrolling patients with IgAN (IgA Nephropathy) to find out if oral atrasentan will delay worsening of kidney functions in comparison to placebo. Subjects will be asked to complete questionnaires, do a physical exam, perform ECG, give blood and urine samples, and weigh themselves.
99 years and younger
All genders
The purpose of the study is to define the safety and tolerability of ascending doses of VB119 in subjects with primary membranous nephropathy. Study drug will be administered intravenously. The Data Review Committee will review safety data and determine dosage based on available safety, PD and other clinical data. Participants …
1 - 10 of 14